BiotechTube
Home/Esperion Therapeutics/Mark A. Glickman
MA

Mark A. Glickman

Senior Vice President, Chief Financial Officer and Treasurer

Esperion Therapeutics

Therapeutic Areas

CardiovascularMetabolic Disorders

Esperion Therapeutics Pipeline

DrugIndicationPhase
NEXLETOL (bempedoic acid)LDL-C lowering in HeFH/ASCVDPhase 4
NEXLIZET (bempedoic acid/ezetimibe)LDL-C lowering in HeFH/ASCVDPhase 4
Bempedoic AcidCardiovascular Outcomes (Primary Prevention)Phase 3
Next-Gen FDCsComprehensive Lipid ManagementDiscovery

Leadership Team at Esperion Therapeutics

SL
Sheldon L. Koenig
President and Chief Executive Officer
JM
JoAnne M. Foody
Chief Medical Officer
BJ
Benjamin J. Quirk
Senior Vice President, General Counsel and Corporate Secretary
TM
Timothy M. Mayleben
Executive Advisor, Former CEO
View full Esperion Therapeutics profile